Cancer Immunology, Immunotherapy

, Volume 57, Issue 10, pp 1505–1509 | Cite as

Translating immunity into cancer therapy: new findings from the first conference of the European Society for Cancer Immunology and Immunotherapy, an ESMO-EIS held in Athens, 15–17 November 2007

  • Graham PawelecEmail author
  • Sonia Perez
Meeting Report

The discussion on breast cancer immunotherapy at this first ESMO-supported ESCII conference in Athens was perhaps appropriate given that the very name “cancer” derives from the ancient Greeks’ observations on the external manifestations of breast tumours, with Galen noting that the veins in breast cancer are dilated and similar in appearance to crabs’ legs on both sides of the body, indicating presence of the tumour. Important modern concepts and therapeutic targets of inflammation and angiogenesis were presaged by their observations, and the effect of diet on causation was also perceived. This 2-day meeting, 2000+ years later, considered the current position of immunotherapy from many points of view, including the issue of cancer and inflammation, adoptive therapy by antibodies and cells, active immunotherapy with vaccines and the critical role of immunity versus tolerance. We present here a brief personal view of the highlights of the meeting, organised by H. Mellstedt, Stockholm,...


Cervical Cancer Adoptive Immunotherapy Active Immunotherapy Early Stage Breast Cancer Patient Super Paramagnetic Iron Oxide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Schiller JT, Lowy DR (2006) Prospects for cervical cancer prevention by human papillomavirus vaccination. Cancer Res 66:10229–10232PubMedCrossRefGoogle Scholar
  2. 2.
    Toes RE, Offringa R, Blom RJ, Melief CJ, Kast WM (1996) Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci USA 93:7855–7860PubMedCrossRefGoogle Scholar
  3. 3.
    Mittendorf EA, Gurney JM, Storrer CE, Shriver CD, Ponniah S, Peoples GE (2006) Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancer. Surgery 139:407–418PubMedCrossRefGoogle Scholar
  4. 4.
    Hanna MG Jr, Key ME (1982) Immunotherapy of metastases enhances subsequent chemotherapy. Science 217:367–369PubMedCrossRefGoogle Scholar
  5. 5.
    Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD (2007) Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450:903–907PubMedCrossRefGoogle Scholar
  6. 6.
    Borrebaeck CA, Wingren C (2007) High-throughput proteomics using antibody microarrays: an update. Expert Rev Mol Diagn 7:673–686PubMedCrossRefGoogle Scholar
  7. 7.
    Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K (2000) Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 356:1795–1799PubMedCrossRefGoogle Scholar
  8. 8.
    Bryceson YT, March ME, Ljunggren HG, Long EO (2006) Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev 214:73–91PubMedCrossRefGoogle Scholar
  9. 9.
    Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100:8372–8377PubMedCrossRefGoogle Scholar
  10. 10.
    Nair S, Boczkowski D, Fassnacht M, Pisetsky D, Gilboa E (2007) Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. Cancer Res 67:371–380PubMedCrossRefGoogle Scholar
  11. 11.
    Griffioen AW, van der Schaft DW, Barendsz-Janson AF, Cox A, Struijker Boudier HA, Hillen HF, Mayo KH (2001) Anginex, a designed peptide that inhibits angiogenesis. Biochem J 354:233–242PubMedCrossRefGoogle Scholar
  12. 12.
    De Vries IJ, Bernsen MR, van Geloof WL, Scharenborg NM, Lesterhuis WJ, Rombout PD, Van Muijen GN, Figdor CG, Punt CJ, Ruiter DJ, Adema GJ (2007) In situ detection of antigen-specific T cells in cryo-sections using MHC class I tetramers after dendritic cell vaccination of melanoma patients. Cancer Immunol Immunother 56:1667–1676PubMedCrossRefGoogle Scholar
  13. 13.
    Santegoets SJ, Schreurs MW, Masterson AJ, Liu YP, Goletz S, Baumeister H, Kueter EW, Lougheed SM, van den Eertwegh AJ, Scheper RJ, Hooijberg E, de Gruijl TD (2006) In vitro priming of tumor-specific cytotoxic T lymphocytes using allogeneic dendritic cells derived from the human MUTZ-3 cell line. Cancer Immunol Immunother 55:1480–1490PubMedCrossRefGoogle Scholar
  14. 14.
    Kiessling R, De Geer A, Johansson C, Poschke I, Triulzi C, Vertuani S (2007) Progress in vaccination against cancer-7: report of the meeting in Stockholm, September 10–11, 2007. Cancer Immunol Immunother Nov 20; [Epub ahead of print]Google Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  1. 1.Center for Medical ResearchTübingenGermany
  2. 2.Cancer Immunology and Immunotherapy CenterSaint Savas Cancer HospitalAthensGreece

Personalised recommendations